SVR₁₂ according to baseline patient characteristics and on-treatment HCV viral decline.

SVR12 according to baseline patient characteristics and on-treatment HCV viral decline.</p

Baseline patient characteristics.

Baseline patient characteristics.</p

Characteristics of HBeAg-negative HBsAg carriers according to their hepatitis activities.

<p>Data are expressed as median (25th, 75th quartile) or number (percentage) as indicated.</p

Long-term events of groups according to their hepatitis activities.

<p>Data are expressed as median (25th, 75th quartile) or number (percentage) as indicated.</p>†<p>P<.001,</p>*<p>P<.05 compared with its baseline level.</p>‡<p>P for trend.</p

Characteristics of patients according to HBV genotype B or C.

<p>Data are expressed as median (25th, 75th quartile) or number (percentage) as indicated.</p>†<p>P<.001 compared with its baseline level.</p

Predictors for HBsAg decline >1 log at end-of-follow-up, HBsAg loss and HBeAg-negative hepatitis by multivariate analysis.

†<p>P = .001,</p>*<p>P<.05.</p

Study flow.

Study flow.</p

Safety summary.

Safety summary.</p

The flow chart of patient enrollment. EOF = end-of-follow-up, HCC = hepatocellular carcinoma.

<p>The flow chart of patient enrollment. EOF = end-of-follow-up, HCC = hepatocellular carcinoma.</p

Virologic responses.

Virologic responses.</p